Evidence map›Paper›PMID 42274636›Full record

ArticleAntimicrobial agents and chemotherapy2026

Nemonoxacin pharmacokinetics/pharmacodynamics against

Chunye Qi, Ruohao Zhang, Xingyi Qu, Xiaofen Liu, Xingchen Bian, Fengjia Zhu, Jing Chen, Xin Li, Jing Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chunye Qi *Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Ruohao Zhang *Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Xingyi QuInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Xiaofen LiuInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-5526-1502
Xingchen BianClinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-2554-5317
Fengjia ZhuResearch and Development Center, Zhejiang Medicine Co., Ltd., Zhejiang, China.
Jing ChenResearch and Development Center, Zhejiang Medicine Co., Ltd., Zhejiang, China.
Xin LiInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.ORCID 0009-0003-9073-4349
Jing ZhangInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-2966-9149

Funding

Hunan Provincial Key Laboratory of Anti-Resistance Microbial Drugs 2023TP1013Science and Technology Innovation Plan Of Shanghai Science and Technology Commission 23YF1404000
6 · The paper itself

Abstract

Nemonoxacin, a novel non-fluorinated quinolone, is approved for community-acquired pneumonia, but its efficacy against uncomplicated urinary tract infections (uUTIs) caused by

Indexed as

Anti-Bacterial AgentsEscherichia coliEscherichia coli InfectionsQuinolonesUrinary Tract InfectionsHumansMicrobial Sensitivity TestsMonte Carlo MethodAnti-Bacterial AgentsnemonoxacinQuinolonesEscherichia coliin vitropharmacokinetics/pharmacodynamics modelingnemonoxacinurinary tract infections

Identifiers

PMID42274636
PMCPMC13321827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.